{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:33:48Z","timestamp":1790508828017,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P01 CA225618"],"award-info":[{"award-number":["P01 CA225618"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA06973"],"award-info":[{"award-number":["P30 CA06973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtct.2024.03.018","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:36:57Z","timestamp":1711096617000},"page":"588-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide"],"prefix":"10.1016","volume":"30","author":[{"given":"Jonaphine Rae","family":"Mata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-7182","authenticated-orcid":false,"given":"Natalie","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alexander J.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.03.018_bib0001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.03.018_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620720948743","article-title":"Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation","volume":"11","author":"Chen","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.03.018_bib0003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Ozdemir","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"10.1016\/j.jtct.2024.03.018_bib0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.03.018_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.18620\/ctt-1866-8836-2020-9-4-37-47","article-title":"Risk factors for graft failure in allogeneic hematopoietic stem cell transplantation: a single-center study","volume":"9","author":"Novitzky-Basso","year":"2020","journal-title":"Cell Ther Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.03.018_bib0006","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.bbmt.2013.12.021","article-title":"Risk factors for graft failure and survival after reduced intensity (RIC) conditioning allogeneic hematopoietic cell transplantation (HCT) for myelofibrosis","volume":"20","author":"Glotzbecker","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2024.03.018_bib0007","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1182\/bloodadvances.2023009786","article-title":"Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic","volume":"7","author":"Devine","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jtct.2024.03.018_bib0008","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2024.03.018_bib0009","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood-2019-124208","article-title":"Risk Factors for primary and secondary graft failure in allogenic hematopoietic cell transplantation: a single center study","volume":"134","author":"Al-Shaibani","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.018_bib0010","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.3324\/haematol.2015.140509","volume":"101","author":"Sun","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.018_bib0011","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/10428194.2014.930849","article-title":"Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients","volume":"56","author":"Ferr\u00e0","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.018_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7150\/ijms.6337","article-title":"Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Xiao","year":"2014","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.018_bib0013","first-page":"293","article-title":"Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes","volume":"27","author":"Chen","year":"2022","journal-title":"Hematol (United Kingdom)"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.018_bib0014","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2024.03.018_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Increasing the dose of total body irradiation to decrease graft failure associated with HLA-haploidentical transplantation for patients with severe hemoglobinopathies. A single institution prospective clinical trial. HHS Public Access","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2024.03.018_bib0016","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood-2019-121659","article-title":"Graft failure after haploidentical hematopoietic stem cell transplantation","volume":"134","author":"Hickey","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.018_bib0017","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Posttransplantation cyclophosphamide-based graft versus host disease prophylaxis with non-myeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.018_bib0018","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-018-3278-9","article-title":"Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"97","author":"Shimomura","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.018_bib0019","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.018_bib0020","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.03.018_bib0021","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.018_bib0022","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.2000.02422.x","article-title":"High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients","volume":"111","author":"Ljungman","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.03.018_bib0023","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1086\/428060","article-title":"Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation","volume":"40","author":"Zerr","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.018_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2004.05254.x","article-title":"Impact of human herpesvirus-6 after haematopoietic stem cell transplantation","volume":"128","author":"Hentrich","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.03.018_bib0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1086\/339411","article-title":"Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors","volume":"185","author":"Yoshikawa","year":"2002","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2024.03.018_bib0026","doi-asserted-by":"crossref","first-page":"397.e1","DOI":"10.1016\/j.jtct.2023.02.022","article-title":"Once-daily foscarnet is effective for human herpesvirus 6 reactivation after hematopoietic stem cell transplantation","volume":"29","author":"Vittayawacharin","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.018_bib0027","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0308-2261(21)00052-7","article-title":"Marrow transplantation for treatment of aplastic anaemia","volume":"7","author":"Storb","year":"1978","journal-title":"Clin Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.018_bib0028","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/leu.2015.75","article-title":"Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"29","author":"Olsson","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.jtct.2024.03.018_bib0029","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2009-03-208355","article-title":"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose","volume":"114","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.018_bib0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.bbmt.2014.05.021","article-title":"Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"20","author":"T\u00f6rl\u00e9n","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.03.018_bib0031","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbmt.2015.01.025","article-title":"Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Remberger","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2024.03.018_bib0032","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.25826","volume":"95","author":"Maffini","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2024.03.018_bib0033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.13332","article-title":"Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation","volume":"104","author":"Salas","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.03.018_bib0034","doi-asserted-by":"crossref","first-page":"181.e1","DOI":"10.1016\/j.jtct.2022.12.005","article-title":"Effect of CD34+ cell dose on the outcomes of allogeneic stem cell transplantation with post-transplantation cyclophosphamide","volume":"29","author":"Pedraza","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"10.1016\/j.jtct.2024.03.018_bib0035","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Schoch","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2024.03.018_bib0036","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2020.06.012","article-title":"Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic hodgkin lymphoma: a retrospective cohort Study","volume":"26","author":"Paul","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T01:27:52Z","timestamp":1748741272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724002914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666636724002914"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}